Assembly Biosciences (ASMB) presented data from its herpes simplex virus or HSV helicase-primase inhibitor candidates for recurrent genital herpes, ABI-5366 and ABI-1179. The company said the preclinical data supported ABI-5366's entry into Phase 1 clinical evaluation. ABI-5366 showed low nanomolar activity against both HSV-1 and HSV-2, including broad activity against HSV clinical isolates, and specificity for HSV. ABI-1179 has showed low nanomolar activity across HSV-1 and HSV-2 lab strains and clinical isolates, including acyclovir-resistant isolates.
The company said it continues to advance these candidates and look forward to sharing further updates with the herpesvirus community, including interim ABI-5366 Phase 1a first-in-human data expected in the third quarter of the current year. Assembly Bio plans to initiate a Phase 1a/b first-in-human study of ABI-1179 by the end of 2024.
Shares of Assembly Biosciences are down 6% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.